Suspension of trading

Income Statement Checkpoint Therapeutics, Inc.

Stocks

CKPT

US1628282063

Biotechnology & Medical Research

Delayed Nasdaq 16:00:00 2025-05-29 EDT			5-day change	1st Jan Change
4.260 ^USD	+0.71%		-.--%	-

25-06-01	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
25-05-30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI

4b6fafd226250e18.z1u_lA5x5LeeEy7qzq1wi7QMwC9N3A1BbYYkesEzp_U.-2P19ToZguL2WEympPgWvcY7sFsIj2ALOLdsCohp6YX9MYmhTB2d_f8hQQ

Published financial data: CHECKPOINT THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	1.07M	268K	192K	103K	41K
Total Revenues	1.07M	268K	192K	103K	41K
Cost of Goods Sold, Total	16.35M	48.45M	49.82M	43.57M	36.15M
Gross Profit	-15.28M	-48.18M	-49.63M	-43.46M	-36.11M
Selling General & Admin Expenses, Total	7.92M	8.54M	8.7M	8.68M	20.06M
Other Operating Expenses, Total	7.92M	8.54M	8.7M	8.68M	20.06M
Operating Income	-23.2M	-56.72M	-58.33M	-52.15M	-56.17M
Interest Expense, Total	-	-	-	-	-
Interest And Investment Income	120K	53K	160K	84K	11K
Net Interest Expenses	120K	53K	160K	84K	11K
Currency Exchange Gains (Loss)	-	-	-	-	-4K
Other Non Operating Income (Expenses)	-	-	-4.45M	217K	-73K
EBT, Excl. Unusual Items	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
EBT, Incl. Unusual Items	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Earnings From Continuing Operations	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Net Income to Company	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Net Income - (IS)	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Net Income to Common Incl Extra Items	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Net Income to Common Excl. Extra Items	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Per Share Items
Net EPS - Basic	-4.13	-6.7	-6.09	-1.87	-1.42
Basic EPS - Continuing Operations	-4.13	-6.7	-6.09	-1.87	-1.42
Basic Weighted Average Shares Outstanding	5.58M	8.46M	10.29M	27.74M	39.67M
Net EPS - Diluted	-4.13	-6.7	-6.09	-1.87	-1.42
Diluted EPS - Continuing Operations	-4.13	-6.7	-6.09	-1.87	-1.42
Diluted Weighted Average Shares Outstanding	5.58M	8.46M	10.29M	27.74M	39.67M
Normalized Basic EPS	-2.58	-4.19	-3.8	-1.17	-0.89
Normalized Diluted EPS	-2.58	-4.19	-3.8	-1.17	-0.89
Supplemental Items
EBITA	-23.2M	-56.72M	-58.33M	-52.15M	-56.17M
EBIT	-23.2M	-56.72M	-58.33M	-52.15M	-56.17M
Normalized Net Income	-14.43M	-35.42M	-39.14M	-32.4M	-35.15M
Interest on Long-Term Debt	-	-	-	-	-
Supplemental Operating Expense Items
Marketing Expenses	-	-	-	300K	200K
Selling and Marketing Expenses	-	-	-	300K	200K
General and Administrative Expenses	7.92M	8.54M	8.7M	8.38M	19.86M
Research And Development Expense From Footnotes	16.35M	48.45M	49.82M	43.57M	36.15M
Stock-Based Comp., COGS (Total)	617K	684K	888K	1.17M	5.25M
Stock-Based Comp., G&A Exp. (Total)	2.16M	2.45M	2.04M	1.73M	10M
Total Stock-Based Compensation	2.78M	3.14M	2.92M	2.9M	15.25M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	40.77M	54.74M	12.07M	4.93M	6.6M
Total Cash And Short Term Investments	40.77M	54.74M	12.07M	4.93M	6.6M
Accounts Receivable, Total	20K	17K	73K	-	-
Other Receivables	-	-	-	-	-
Total Receivables	20K	17K	73K	-	-
Prepaid Expenses	1.8M	976K	1.15M	450K	867K
Total Current Assets	42.6M	55.73M	13.29M	5.38M	7.47M
Total Assets	42.6M	55.73M	13.29M	5.38M	7.47M
Liabilities
Accounts Payable, Total	3.44M	16.14M	11.54M	6.57M	6.09M
Accrued Expenses, Total	3.39M	9.61M	9.79M	11.14M	12.35M
Other Current Liabilities	385K	233K	11.45M	711K	1.66M
Total Current Liabilities	7.22M	25.98M	32.77M	18.42M	20.1M
Long-Term Debt	-	-	-	-	-
Total Liabilities	7.22M	25.98M	32.77M	18.42M	20.1M
Common Stock, Total	7K	9K	1K	3K	5K
Additional Paid In Capital	174M	223M	241M	298M	350M
Retained Earnings	-143M	-200M	-262M	-314M	-371M
Comprehensive Income and Other	4.62M	6.6M	1.88M	3.42M	7.64M
Total Common Equity	35.38M	29.75M	-19.48M	-13.05M	-12.62M
Total Equity	35.38M	29.75M	-19.48M	-13.05M	-12.62M
Total Liabilities And Equity	42.6M	55.73M	13.29M	5.38M	7.47M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	7.52M	9.06M	12.95M	35.69M	83.76M
ECS Total Common Shares Outstanding	6.94M	8.46M	10.29M	27.74M	54.34M
Book Value / Share	5.1	3.52	-1.89	-0.47	-0.23
Tangible Book Value	35.38M	29.75M	-19.48M	-13.05M	-12.62M
Tangible Book Value Per Share	5.1	3.52	-1.89	-0.47	-0.23
Total Debt	0	0	0	0	0
Net Debt	-40.77M	-54.74M	-12.07M	-4.93M	-6.6M
Account Code - Inventory Valuation	3	3	3	3	3
Full Time Employees	10	14	24	23	24
Part Time Employees	-	-	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-23.08M	-56.67M	-62.62M	-51.85M	-56.24M
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	2.78M	3.14M	2.92M	2.9M	15.25M
Other Operating Activities, Total	5.52M	7.63M	6.75M	4.15M	8.71M
Change In Accounts Receivable	6K	3K	-56K	73K	-
Change In Accounts Payable	-833K	18.76M	-4.38M	-3.57M	1.6M
Change in Other Net Operating Assets	-941K	828K	-173K	699K	-417K
Cash from Operations	-16.55M	-26.31M	-57.55M	-47.59M	-31.1M
Sale (Purchase) of Intangible assets	-	-	-	-	-
Cash from Investing	-	-	-	-	-
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	33.28M	41.28M	17.62M	44.76M	35.18M
Repurchase of Common Stock	-	-	-1.7M	-	-
Other Financing Activities, Total	-2.03M	-1.01M	-1.03M	-4.3M	-2.41M
Cash from Financing	31.25M	40.27M	14.89M	40.45M	32.78M
Net Change in Cash	14.7M	13.96M	-42.67M	-7.14M	1.68M
Supplemental Items
Cash Interest Paid	-	-	-	-	-
Levered Free Cash Flow	-13.56M	-12.72M	-26.97M	-43.27M	-18.6M
Unlevered Free Cash Flow	-13.56M	-12.72M	-26.97M	-43.27M	-18.6M
Change In Net Working Capital	1.84M	-19.6M	-6.56M	13.58M	-1.25M
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-41.69	-72.11	-105.65	-349.18	-546.48
Return on Total Capital	-53.48	-108.87	-710.48	200.38	273.52
Return On Equity %	-85.13	-174.03	-1.22K	318.76	438.14
Return on Common Equity	-85.13	-174.03	-1.22K	318.76	438.14
Margin Analysis
Gross Profit Margin %	-1.43K	-17.98K	-25.85K	-42.2K	-88.08K
SG&A Margin	740.69	3.19K	4.53K	8.43K	48.93K
EBITA Margin %	-2.17K	-21.17K	-30.38K	-50.63K	-137K
EBIT Margin %	-2.17K	-21.17K	-30.38K	-50.63K	-137K
Income From Continuing Operations Margin %	-2.16K	-21.15K	-32.62K	-50.34K	-137K
Net Income Margin %	-2.16K	-21.15K	-32.62K	-50.34K	-137K
Net Avail. For Common Margin %	-2.16K	-21.15K	-32.62K	-50.34K	-137K
Normalized Net Income Margin	-1.35K	-13.22K	-20.39K	-31.46K	-85.73K
Levered Free Cash Flow Margin	-1.27K	-4.75K	-14.05K	-42.01K	-45.37K
Unlevered Free Cash Flow Margin	-1.27K	-4.75K	-14.05K	-42.01K	-45.37K
Asset Turnover
Asset Turnover	0.03	0.01	0.01	0.01	0.01
Receivables Turnover (Average Receivables)	46.48	14.49	4.27	-	-
Short Term Liquidity
Current Ratio	5.9	2.14	0.41	0.29	0.37
Quick Ratio	5.65	2.11	0.37	0.27	0.33
Operating Cash Flow to Current Liabilities	-2.29	-1.01	-1.76	-2.58	-1.55
Days Sales Outstanding (Average Receivables)	7.87	25.2	85.55	-	-
Average Days Payable Outstanding	72.93	73.74	101.36	75.84	64.09
Long Term Solvency
Total Debt/Equity	-	-	-	-	-
Total Debt / Total Capital	-	-	-	-	-
LT Debt/Equity	-	-	-	-	-
Long-Term Debt / Total Capital	-	-	-	-	-
Total Liabilities / Total Assets	16.94	46.62	246.6	342.6	268.99
EBIT / Interest Expense	-	-	-	-	-
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-37.41	-74.93	-28.36	-46.35	-60.19
Gross Profit, 1 Yr. Growth %	-13.25	215.28	3	-12.43	-16.92
EBITA, 1 Yr. Growth %	-6.64	144.49	2.84	-10.6	7.72
EBIT, 1 Yr. Growth %	-6.64	144.49	2.84	-10.6	7.72
Earnings From Cont. Operations, 1 Yr. Growth %	-6.61	145.53	10.51	-17.21	8.47
Net Income, 1 Yr. Growth %	-6.61	145.53	10.51	-17.21	8.47
Normalized Net Income, 1 Yr. Growth %	-6.61	145.53	10.51	-17.21	8.47
Diluted EPS Before Extra, 1 Yr. Growth %	-40.94	62.08	-9.14	-69.3	-24.15
Accounts Receivable, 1 Yr. Growth %	-23.08	-15	329.41	-	-
Total Assets, 1 Yr. Growth %	57.96	30.83	-76.15	-59.53	38.92
Tangible Book Value, 1 Yr. Growth %	87.72	-15.92	-165.5	-33.03	-3.23
Common Equity, 1 Yr. Growth %	87.72	-15.92	-165.5	-33.03	-3.23
Cash From Operations, 1 Yr. Growth %	-22.56	58.94	118.79	-17.31	-34.65
Levered Free Cash Flow, 1 Yr. Growth %	-11.79	-6.19	112.06	60.43	-57.01
Unlevered Free Cash Flow, 1 Yr. Growth %	-11.79	-6.19	112.06	60.43	-57.01
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-44.78	-60.39	-57.62	-38.01	-53.79
Gross Profit, 2 Yr. CAGR %	-28.8	65.38	80.21	-5.03	-14.7
EBITA, 2 Yr. CAGR %	-20.53	51.08	58.56	-4.12	-1.87
EBIT, 2 Yr. CAGR %	-20.53	51.08	58.56	-4.12	-1.87
Earnings From Cont. Operations, 2 Yr. CAGR %	-20.33	51.43	64.72	-4.35	-5.23
Net Income, 2 Yr. CAGR %	-20.33	51.43	64.72	-4.35	-5.23
Normalized Net Income, 2 Yr. CAGR %	-20.33	51.43	64.72	-4.35	-5.23
Diluted EPS Before Extra, 2 Yr. CAGR %	-43.03	-2.16	21.35	-47.19	-51.75
Accounts Receivable, 2 Yr. CAGR %	-88.57	-19.14	91.05	-	-
Total Assets, 2 Yr. CAGR %	30.8	43.76	-44.14	-68.93	-25.02
Tangible Book Value, 2 Yr. CAGR %	73.11	25.63	-25.79	-33.77	-19.5
Common Equity, 2 Yr. CAGR %	73.11	25.63	-25.79	-33.77	-19.5
Cash From Operations, 2 Yr. CAGR %	-19.91	10.94	86.48	34.5	-26.49
Levered Free Cash Flow, 2 Yr. CAGR %	-4.81	-9.03	41.05	84.45	-16.95
Unlevered Free Cash Flow, 2 Yr. CAGR %	-4.81	-9.03	41.05	84.45	-16.95
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-14.74	-57.56	-51.74	-54.16	-46.52
Gross Profit, 3 Yr. CAGR %	-4.15	16.92	41.24	41.68	-9.17
EBITA, 3 Yr. CAGR %	0.62	15.58	32.9	30.99	-0.32
EBIT, 3 Yr. CAGR %	0.62	15.58	32.9	30.99	-0.32
Earnings From Cont. Operations, 3 Yr. CAGR %	0.59	15.94	36.33	30.97	-0.25
Net Income, 3 Yr. CAGR %	0.59	15.94	36.33	30.97	-0.25
Normalized Net Income, 3 Yr. CAGR %	0.59	15.94	36.33	30.97	-0.25
Diluted EPS Before Extra, 3 Yr. CAGR %	-25.57	-19.27	-4.55	-23.25	-40.41
Accounts Receivable, 3 Yr. CAGR %	-60.76	-77.7	41.07	-	-
Total Assets, 3 Yr. CAGR %	25.77	30.81	-21.01	-49.83	-48.82
Tangible Book Value, 3 Yr. CAGR %	32.99	36.07	1.11	-28.29	-24.85
Common Equity, 3 Yr. CAGR %	32.99	36.07	1.11	-28.29	-24.85
Cash From Operations, 3 Yr. CAGR %	2.3	0.64	39.12	42.2	5.74
Levered Free Cash Flow, 3 Yr. CAGR %	10.26	-5.27	20.62	47.23	13.51
Unlevered Free Cash Flow, 3 Yr. CAGR %	10.26	-5.27	20.62	47.23	13.51
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	12.62	-36.37	-35.54	-50.61	-52.57
Gross Profit, 5 Yr. CAGR %	7.32	22.18	23.39	7.59	15.44
EBITA, 5 Yr. CAGR %	11.9	20.68	20.7	7.26	17.72
EBIT, 5 Yr. CAGR %	11.9	20.68	20.7	7.26	17.72
Earnings From Cont. Operations, 5 Yr. CAGR %	10.69	20.33	22.53	7.35	17.87
Net Income, 5 Yr. CAGR %	10.69	20.33	22.53	7.35	17.87
Normalized Net Income, 5 Yr. CAGR %	10.69	20.33	22.53	7.35	17.87
Diluted EPS Before Extra, 5 Yr. CAGR %	-21.75	-8.46	-9.5	-31.87	-27.34
Accounts Receivable, 5 Yr. CAGR %	-21	-53.95	-26.09	-	-
Total Assets, 5 Yr. CAGR %	-3.41	9.15	-9.1	-26.4	-22.64
Tangible Book Value, 5 Yr. CAGR %	-5.28	-1.64	5.31	2.02	-7.7
Common Equity, 5 Yr. CAGR %	-5.28	-1.64	5.31	2.02	-7.7
Cash From Operations, 5 Yr. CAGR %	71.73	21.46	30.07	13.02	7.79
Levered Free Cash Flow, 5 Yr. CAGR %	-	1.49	21.67	23.66	3.89
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	1.31	21.67	23.66	3.89